immunotherapy targeting alpha synuclein, tau and TDP-43
 

Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs

http://www.drugsfreelist.com/medical...sease_Programs
Date: 05 Jan 2011


Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs.

The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson`s disease, Alzheimer`s disease and amyotrophic lateral sclerosis (ALS).